搭載山奈酚之抗角膜血管新生眼部奈米藥物研製及其作用機制、療效評估探討

Medicine and Dentistry

1. Antiangiogenic Activity 100%
2. Corneal Neovascularization 100%
3. Kaempferol 100%
4. Nanomedicine 100%
5. Nanoparticle 83%
6. Intraocular Drug Administration 50%
7. Therapeutic Agent 50%
8. Eye Disease 50%
9. Eye Drops 33%
10. Bioavailability 33%
11. Endothelium Cell 33%
12. Vascular Endothelium 33%
13. Angiogenesis 33%
14. Integrin 33%
15. Low Drug Dose 16%
16. Biological Activity 16%
17. Retinal Detachment 16%
18. Ophthalmology 16%
19. Contact Lens 16%
20. Visual Acuity 16%
21. Aspartic Acid 16%
22. Endothelial Cell 16%
23. In Vitro 16%
24. Public Health 16%
25. Graft Failure 16%
26. Drug Bioavailability 16%
27. Hypoxia 16%
28. Blood Flow 16%
29. Vision 16%
30. Cataract 16%
31. Arginine 16%
32. Flavonoid 16%

Pharmacology, Toxicology and Pharmaceutical Science

1. Kaempferol 100%
2. Cornea Neovascularization 100%
3. Nanomedicine 100%
4. Nanoparticle 83%
5. Eye Disease 50%
6. Bioavailability 50%
7. Eye Drops 33%
8. Integrin 33%
9. Inflammation 33%
10. Rabbit Model 16%
11. Ocular Drug 16%
12. Agents Acting on the Eye 16%
13. Flavonoid 16%
14. Neovascularization (Pathology) 16%
15. Graft Failure 16%
16. Retina Detachment 16%
17. Drug Concentration 16%
18. Hypoxia 16%
19. Aspartic Acid 16%
20. Arginine 16%
21. Cataract 16%